Ilaprazole-amoxicillin dual therapy at high dose as a first-line treatment for helicobacter pylori infection in Hainan: a single-center, open-label, noninferiority, randomized controlled trial.

Zhang, Xiao-Dong; Zhang, Da-Ya; Chen, Run-Xiang; Chen, Shi-Ju; Chen, Chen; Zeng, Fan; Huang, Shi-Mei; Li, Da; Bai, Fei-Hu

Zhang, Xiao-Dong; Zhang, Da-Ya; Chen, Run-Xiang; Chen, Shi-Ju; Chen, Chen; Zeng, Fan; Huang, Shi-Mei; Li, Da; Bai, Fei-Hu.

Affiliation

Zhang XD; Graduate School, Hainan Medical University, Haikou, China.
Zhang DY; Graduate School, Hainan Medical University, Haikou, China.
Chen RX; Graduate School, Hainan Medical University, Haikou, China.
Chen SJ; Graduate School, Hainan Medical University, Haikou, China.
Chen C; Graduate School, Hainan Medical University, Haikou, China.
Zeng F; Graduate School, Hainan Medical University, Haikou, China.
Huang SM; Graduate School, Hainan Medical University, Haikou, China.
Li D; Graduate School, Hainan Medical University, Haikou, China.
Bai FH; Department of Gastroenterology, The Second Affiliated Hospital of Hainan Medical University, Yehai Avenue, #368, Longhua District, Haikou, Hainan Province, China. 328473521@qq.com.

BMC Gastroenterol ; 23(1): 249, 2023 Jul 24.

Article in En | MEDLINE | ID: mdl-37488516

Subject(s)

Helicobacter Infections; Helicobacter pylori; Humans; Amoxicillin; 2-Pyridinylmethylsulfinylbenzimidazoles; Bismuth; Furazolidone

Key words

Dual therapy; Eradication rate; Helicobacter pylori; Ilaprazole; Noninferiority; Quadruple therapy

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Helicobacter pylori / Helicobacter Infections Type of study: Clinical_trials / Guideline Limits: Humans Language: En Journal: BMC Gastroenterol Journal subject: GASTROENTEROLOGIA Year: 2023 Type: Article Affiliation country: China

Fulltext

XML

PubMed Links

Search on Google